Company news
Abbisko Cayman Limited news in 2026
Abbisko Cayman Limited's news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 2, 2026
Change of company name
November 1, 2026
Next Day Disclosure Returns
October 30, 2026
Next Day Disclosure Returns
October 29, 2026
Next Day Disclosure Returns
October 27, 2026
Next Day Disclosure Returns
October 23, 2026
Next Day Disclosure Returns
October 21, 2026
Voluntary announcement - abbisko therapeutics' lavengratinib (ABSK061) for the treatment of achondroplasia granted Orphan Designation by EMA
October 20, 2026
Next Day Disclosure Returns
October 20, 2026
Next Day Disclosure Returns
October 15, 2026
Next Day Disclosure Returns
October 14, 2026
Next Day Disclosure Returns
October 8, 2026
Next Day Disclosure Returns
October 7, 2026
Next Day Disclosure Returns
October 6, 2026
Next Day Disclosure Returns
October 5, 2026
Next Day Disclosure Returns
October 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Next Day Disclosure Returns
September 29, 2026
Next Day Disclosure Returns
September 28, 2026
2026 Interim report
September 22, 2026
Voluntary announcement - abbisko therapeutics announces positive preliminary phase II results with lavengratinib (ABSK061) for the treatment of achondroplasia
September 20, 2026
Poll results of the extraordinary general meeting held on September 17, 2026
September 17, 2026
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
April 22, 2026
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 12, 2026